Regulatory submission for the treatment of anaemia of chronic kidney disease based on the ASCEND phase III clinical trial programme, consisting of five trials that all met their primary efficacy and safety endpoints in non-dialysis and dialysis patients US FDA regulatory submission acceptance is the third major regulatory milestone for daprodustat
National program establishes early care management, technology innovation and large health system engagement as a strategic priority for supporting the 34 million U.S.